Kumarasiri Akila, Chetty Indrin J, Devpura Suneetha, Pradhan Deepak, Aref Ibrahim, Elshaikh Mohamed A, Movsas Benjamin
Department of Radiation Oncology, Henry Ford Health, Detroit, Michigan, USA.
J Appl Clin Med Phys. 2024 Mar;25(3):e14198. doi: 10.1002/acm2.14198. Epub 2023 Nov 12.
To investigate the impact of reducing Clinical Target Volume (CTV) to Planning Target Volume (PTV) margins on delivered radiation therapy (RT) dose and patient reported quality-of-life (QOL) for patients with localized prostate cancer.
Twenty patients were included in a single institution IRB-approved prospective study. Nine were planned with reduced margins (4 mm at prostate/rectum interface, 5 mm elsewhere), and 11 with standard margins (6/10 mm). Cumulative delivered dose was calculated using deformable dose accumulation. Each daily CBCT dataset was deformed to the planning CT (pCT), dose was computed, and accumulated on the resampled pCT using a parameter-optimized, B-spline algorithm (Elastix, ITK/VTK). EPIC-26 patient reported QOL was prospectively collected pre-treatment, post-treatment, and at 2-, 6-, 12-, 18-, 24-, 36-, 48-, and 60-month follow-ups. Post -RT QOL scores were baseline corrected and standardized to a [0-100] scale using EPIC-26 methodology. Correlations between QOL scores and dosimetric parameters were investigated, and the overall QOL differences between the two groups (QOL -QOL ) were calculated.
The median QOL follow-up length for the 20 patients was 48 months. Difference between delivered dose and planned dose did not reach statistical significance (p > 0.1) for both targets and organs at risk between the two groups. At 4 years post-RT, standardized mean QOL -QOL were improved for Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, and Sexual EPIC domains by 3.5, 14.8, 10.2, and 16.1, respectively (higher values better). The control group showed larger PTV/rectum and PTV/bladder intersection volumes (7.2 ± 5.8, 18.2 ± 8.1 cc) than the margin-reduced group (2.6 ± 1.8, 12.5 ± 8.3 cc), though the dose to these intersection volumes did not reach statistical significance (p > 0.1) between the groups. PTV/rectum intersection volume showed a moderate correlation (r = -0.56, p < 0.05) to Bowel EPIC domain.
Results of this prospective study showed that margin-reduced group exhibited clinically meaningful improvement of QOL without compromising the target dose coverage.
探讨降低局部前列腺癌患者临床靶区(CTV)至计划靶区(PTV)的边界对所给予的放射治疗(RT)剂量及患者报告的生活质量(QOL)的影响。
20例患者纳入一项经单一机构机构审查委员会批准的前瞻性研究。9例患者采用缩小边界计划(前列腺/直肠界面处4 mm,其他部位5 mm),11例采用标准边界计划(6/10 mm)。使用可变形剂量累积计算累积给予剂量。将每个每日CBCT数据集变形至计划CT(pCT),计算剂量,并使用参数优化的B样条算法(Elastix,ITK/VTK)在重新采样的pCT上进行累积。前瞻性收集EPIC - 26患者报告的生活质量,时间点为治疗前、治疗后以及2个月、6个月、12个月、18个月、24个月、36个月、48个月和60个月随访时。放疗后生活质量评分进行基线校正,并使用EPIC - 26方法标准化为[0 - 100]量表。研究生活质量评分与剂量学参数之间的相关性,并计算两组之间的总体生活质量差异(QOL - QOL)。
20例患者的生活质量随访时间中位数为48个月。两组在靶区和危及器官方面,给予剂量与计划剂量之间的差异均未达到统计学显著性(p > 0.1)。放疗后4年,尿失禁、尿路刺激/梗阻、肠道和性功能EPIC领域的标准化平均QOL - QOL分别改善了3.5、14.8、10.2和16.1(数值越高越好)。对照组的PTV/直肠和PTV/膀胱相交体积(7.2 ± 5.8,18.2 ± 8.1 cc)大于边界缩小组(2.6 ± 1.8,12.5 ± 8.3 cc),尽管两组间这些相交体积的剂量未达到统计学显著性(p > 0.1)。PTV/直肠相交体积与肠道EPIC领域呈中度相关性(r = -0.56,p < 0.05)。
这项前瞻性研究结果表明,边界缩小组在不影响靶区剂量覆盖的情况下,生活质量有临床意义的改善。